Our strategy is to develop pharmacologically optimized drug candidates, which are first assessed in healthy volunteers and patients as monotherapy prior to their use in combination regimens designed to achieve improved treatment outcomes in patients. Our initial areas of focus are viral and liver diseases where our team can leverage their in-depth knowledge and expertise to develop potentially best-in-class combination regimens for each disease area with significant unmet medical need.

Aligos Clinical Development Strategy

Combination Therapy is Superior to Monotherapy

Aligos Clinical Development Strategy

* MOA = mechanism of action; PK = pharmacokinetics; PD = pharmacodynamics; SOC = standard of care

• Identify and develop best in class drugs with clinically validated MOAs

• Define safety, pharmacokinetics, and efficacy in Phase 1 as monotherapy

• Combine drugs in Phase 2 and beyond to maximize risk-benefit profile